Voyager Acquisition Corp./Cayman Islands SEC Filing Summary

Voyager Acquisition Corp. recently secured shareholder approval for its merger with Veraxa Biotech AG, but the celebratory news comes with a critical financial twist. This summary provides investors with a clear breakdown of the event, its significant implications, and what you need to know as the company transitions.

1. The Event: Voyager's Merger Approval and Critical Redemptions

Voyager Acquisition Corp., a Special Purpose Acquisition Company (SPAC) designed to take a private company public, has secured shareholder approval for its merger with Veraxa Biotech AG, a private Swiss biotechnology firm. This approval, granted on March 12, 2026, allows Voyager to transform into Veraxa Biotech Holding AG, with Veraxa Biotech AG becoming its wholly-owned subsidiary.

However, this approval came with a critical financial development: a staggering number of Voyager shareholders chose to redeem their shares. From an original trust account holding approximately $250.9 million (representing about 25.09 million shares at $10.00 per share), shareholders redeemed approximately 25 million shares. This action returned $250 million to investors, leaving the combined company with a critically low cash balance of only $885,556 from the SPAC's trust account. This represents an extraordinary redemption rate of approximately 99.65% of the SPAC's initial cash proceeds.

2. Key Dates

The pivotal shareholder meeting for the merger vote took place on March 12, 2026. The official announcement regarding the shareholder approvals and the substantial redemptions followed on March 13, 2026.

3. Context and Background

Voyager Acquisition Corp. formed to identify and merge with a promising private company, offering it a faster path to public markets than a traditional Initial Public Offering (IPO). For Veraxa Biotech AG, this merger aimed to provide significant capital for growth and expansion, alongside the benefits of public listing.

However, the near-total redemption of SPAC funds signals a strong lack of confidence among most of Voyager's original investors in the proposed deal with Veraxa Biotech AG. This extremely high redemption rate suggests significant concerns about Veraxa's business prospects, valuation, or the overall merger terms. Investors clearly prioritized getting their initial capital back rather than holding shares in the new entity.

4. Impact and Significance

Shareholder approval transforms Voyager from a "cash box" entity into an operating business, Veraxa Biotech Holding AG. However, the unprecedented redemption rate fundamentally alters the financial outlook for the combined company.

Instead of a substantial capital infusion, Veraxa Biotech Holding AG will begin its public life with a mere $885,556 from the SPAC's trust account. This severely constrains its ability to fund operations, execute growth strategies, invest in research and development, or pursue future acquisitions. This dramatically changes shareholders' investment profile, shifting from a speculative SPAC investment to a stake in an operating biotech company facing immediate and significant capital challenges.

5. Affected Parties

Here's how this event affects different groups:

• Remaining Voyager Investors: If you held Voyager shares and did not redeem them, your investment converts into shares of Veraxa Biotech Holding AG. Their value will now directly tie to Veraxa's operational performance, market perception, and its ability to navigate severe capital constraints.
• Veraxa Biotech AG's Management and Employees: While achieving public company status, the drastically reduced capital infusion means they operate with far less financial flexibility than anticipated, potentially impacting strategic plans and operational runway.
• Veraxa Biotech AG's Customers: Direct impact is likely minimal, but financial limitations could hamper the company's ability to innovate or expand services.
• The Broader Market: This extremely high redemption rate highlights investor skepticism towards this specific SPAC transaction and potentially broader market sentiment regarding certain de-SPAC opportunities.

6. Next Steps and Future Implications

With shareholder approval secured, the merger will proceed to its official "closing," contingent on satisfying remaining regulatory conditions. Following closing, the exchange will delist Voyager's current stock symbol and replace it with a new ticker, likely for Veraxa Biotech Holding AG, typically within a few business days.

Veraxa Biotech Holding AG's immediate focus will be managing existing operations with severely limited capital. The company will likely need to explore immediate, significant additional financing options, such as debt or equity raises, potentially leading to further dilution for existing shareholders or increased financial leverage. The timeline for closing and subsequent listing typically ranges from a few days to several weeks post-approval.

7. Critical Investor Takeaways

Here are critical takeaways for investors:

• Urgent Need to Understand Veraxa Biotech AG: Investors urgently need a detailed understanding of Veraxa Biotech AG's core business, therapeutic pipeline or products, target markets, competitive advantages, and, crucially, its historical and projected financial performance (revenue, profitability, cash burn, existing debt). Without this, assessing your investment's viability is extremely difficult. This summary cannot provide these details, but they are paramount for your due diligence.
• Extreme Capital Constraint: The near-total redemption (99.65%) means Veraxa Biotech Holding AG will start with less than $1 million from the SPAC trust. This immediate, severe financial challenge requires the company to secure substantial additional funding quickly to sustain operations and execute growth plans.
• High Risk of Dilution: Given the minimal cash, the new company will highly likely pursue additional equity financing. This involves issuing new shares, which could significantly dilute existing shareholders' ownership stake and per-share value.
• Significant Volatility Expected: Companies going public via SPAC mergers with such high redemption rates often experience extreme stock price volatility. The market will closely scrutinize Veraxa's financial health and its ability to raise capital and execute its business plan.
• Elevated De-SPAC Risks: Historically, many companies going public via SPACs, especially those with high redemptions, have seen their stock prices decline post-merger. This transaction carries an exceptionally high "de-SPAC" risk.
• Monitor for Further Filings: Monitor subsequent SEC filings (e.g., Form S-4, 10-K, 10-Q, or further 8-Ks) for detailed financial statements of Veraxa Biotech AG, information on its post-merger capital structure, and any new financing announcements.

This merger transforms Voyager into an operating biotech company, but the unprecedented level of redemptions presents an immediate, formidable financial hurdle. Thorough due diligence on Veraxa Biotech AG's business fundamentals and capital strategy is essential for investors.